http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2698631-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6bc65d461015e06815488d82b5982ae |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M1-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M1-00 |
| filingDate | 2018-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93977ccf66883faba289e18462bd638b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fa896ddb0d7170fc38c042056f91730 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5411837a724abf5755c0dfabe53f4c2d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e5a3f7b5c6c00198aa1dd01f1adfa09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1af23b64ce954fb002390036a1f8838b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6dfc620f9a52e81dc183cacee9c1592c |
| publicationDate | 2019-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2698631-C2 |
| titleOfInvention | Method of treating acute left-ventricular cardiovascular insufficiency in myocardial infarction |
| abstract | FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to emergency cardiology and critical states. In the acute period of acute myocardial infarction (AMI), an oxygen therapy is performed; the preparation is administered: peripheral vasodilators, fibrinolytic agents, anticoagulants, diuretics, artificial pulmonary ventilation with positive end-expiratory pressure, airway defoaming, limiting infusion volume, applying bundles on extremities, and dynamic monitoring of haemodynamics. Then one blood vein is released from one vein, and blood vein solutions are added to the other vein. Herewith, blood viscosity is reduced and her fluidity in blood vessels is improved till haemodynamics stabilization, respiratory and urination functions are observed and hematocrit level is reduced, and hematocrit level should not decrease less than 30 %.EFFECT: method enables to normalize haemodynamics, respiration and excretion parameters by reducing blood viscosity and increasing cardiac muscle performance providing reducing vascular wall resistance to blood movement, during systolic cardiac output of blood in vessels, with lower costs of energy resources of ventricular myocardium than with initial level of blood viscosity.1 cl, 1 ex |
| priorityDate | 2018-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.